Enliven, FDA agree on phase 3 trial design for relcobatinib for chronic myeloid leukemia
Enliven Therapeutics (ELVN) and the FDA agreed on a phase 3 trial design for relcobatinib to treat chronic myeloid leukemia in patients who have failed prior treatments. The ENABLE-2 trial will enroll 450 adults.
How this was made
The 30-second read
Why it matters
The FDA agreement removes a regulatory uncertainty, setting the stage for a pivotal trial that could materially affect the company's valuation.
Market read
A clear trial design approval is a catalyst for ELVN and may influence related oncology biotech stocks.
What to watch
Potential competition from other TKIs and the need for enrollment speed.
Background
Enliven Therapeutics is a clinical‑stage biotech developing relcobatinib for patients with chronic myeloid leukemia who have failed prior therapies.
Ticker impact
Enliven Therapeutics and the FDA agreed on the design of the phase 3 ENABLE-2 trial for relcobatinib in CML.
upward pressure as investors price in potential trial success
Regulatory approval of trial design is a material catalyst for biotech stocks, especially before data read‑outs.
Market effects
May lift sentiment for other CML‑focused biotech firms.
Limited to US biotech sector.
Modest, confined to investors tracking oncology pipelines.
Counterpoint
If the trial design is too ambitious, later data could disappoint, causing a sell‑off.
Key entities
- companyEnliven Therapeutics
Biotech developer of relcobatinib.
- regulatorU.S. Food and Drug Administration
Federal agency overseeing drug approvals.
